Cubist Systematic Strategies’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cubist Systematic Strategies’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,900	Closed	-$140K	–	4382
2023 Q4	$140K	Sell	15,900 -6,600	-29%	-$54.1K	﹤0.01%	3102
2023 Q3	$258K	Buy	22,500 +9,500	+73%	+$183K	﹤0.01%	2663
2023 Q2	$329K	Sell	13,000 -5,800	-31%	-$181K	﹤0.01%	2592
2023 Q1	$606K	Buy	+18,800	New	+$586K	﹤0.01%	2541

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cubist Systematic Strategies's RVNC Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 293,675 shares — an estimated $893K sold.

Cubist Systematic Strategies first reported a position in RVNC in Q1 2018 and held it in 22 quarters. The position peaked at $6.6M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Cubist Systematic Strategies reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 293,675 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $893K.
Cubist Systematic Strategies first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 22 quarters.
Cubist Systematic Strategies's Revance Therapeutics, Inc. position peaked at $6.6M in Q2 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.